Target intelligence / Profile preview

African swine fever virus (ASFV) (ASFV)

Target
ASFV
Molecular classification
Virus, Asfarviridae, Large nucleocytoplasmic DNA virus (NCLDV), Enveloped virus
01

Overview

African swine fever virus (ASFV) is a large, complex, enveloped double-stranded DNA virus that is the sole member of the Asfarviridae family. It is the causative agent of African swine fever, a devastating hemorrhagic disease in domestic and wild pigs that poses a significant threat to the global swine industry and food security (World Organisation for Animal Health, 2023). The virus particle is characterized by a sophisticated multilayered structure, including an outer envelope, a capsid, an inner membrane, and a nucleoprotein core, which facilitates its entry into host macrophages and monocytes (PubMed: 31619540). ASFV employs a wide array of mechanisms to evade the host immune system, such as inhibiting interferon production and modulating cell death pathways (PubMed: 30249168). While there are currently no globally approved vaccines or specific antiviral drugs, the virus particle and its structural proteins serve as primary targets for the development of entry inhibitors, DNA replication blockers, and immunogenic components for vaccine design (PubMed: 33453133). Research into small molecule inhibitors like genistein and apigenin has shown potential in disrupting the viral life cycle, though therapeutic challenges remain due to the virus's genetic complexity and high mortality rate (PubMed: 25107871).

Other names
African swine fever virus virionASFV particlePestis africana suum
02

Mechanism of action

Inhibition of viral DNA polymerase activity, disruption of viral entry and uncoating processes, interference with viral protein synthesis, and inhibition of viral topoisomerase II.

03

Biological functions

Viral entryViral replicationImmune evasionHost cell hijackingApoptosis modulationViral assembly
04

Disease associations

InfectionAfrican swine feverHemorrhagic feverSystemic inflammation
05

Safety considerations

High environmental stability and persistenceExtreme virulence with mortality rates approaching 100%Lack of cross-protection between different viral genotypesRisk of reversion to virulence in live-attenuated vaccine candidatesRequirement for high-containment (BSL-3) facilities for research
06

Interacting drugs

Cidofovir

5 more in the full profile.

07

Biomarkers

ASFV p72 antigenASFV p30 antigenASFV p54 antigenASFV genomic DNA (B646L gene)Anti-ASFV antibodies

Beyond the preview

Go deeper on African swine fever virus (ASFV) (ASFV).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on African swine fever virus (ASFV) (ASFV).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call